Coronary artery disease, leading to myocardial infarction and ischemia, affects millions of people and is one of the leading causes of morbidity and mortality worldwide. Invasive techniques such as coronary artery bypass grafting (CABG) using the saphenous vein (SV) or internal mammary artery (IMA) are used to alleviate the sequelae of arterial occlusion. Unfortunately, restenosis due to proliferation of vascular smooth muscle cells (SMCs) in the grafted venous conduit occurs within months to years with a gradual reduction in patency. Surprisingly, the IMA conduits are spared from the pathologic effects of fibroproliferation. However, the underlying cellular and molecular mechanisms, which are the basis for this difference, are unclear. Inter-related processes are likely to involve factors which promote hyperplasia, inflammation and mitogenesis, leading to progression of the cell cycle and proliferation of SMCs. IGF-1 is a potent mitogen that is released at the site of the hemodynamic-induced graft injury. We examined the PI 3 K-Akt/PKB pathway in the proliferation of SMCs isolated from human SV and IMA of the patients undergoing CABG surgery. We observed differential activity of IGF-1-induced PI 3 K-Akt/PKB activation, which was quantitatively and temporally greater in the SV SMCs as compared to the IMA. Immunoblotting data demonstrated a significantly higher activity of both PI3K and Akt in IGF-1-treated SV SMCs. PDK1 activity was far greater in the SV SMCs than the IMA, in line with its biological action of serine residue phosphorylation of Akt. We also observed an upregulation of IGF-1 receptors (IGF-1R) in the SV SMCs in response to IGF-1 stimulation. The activity of PTEN, a phosphatase that regulate PI 3 K-Akt/PKB pathway, was significantly greater in IMA than in SV SMCs. Transient overexpression of SV SMCs with p-ORFhPTEN inhibited the PKB activity. Upstream effects of PTEN overexpression was a reduction of cell surface IGF-1Rs, which was independent of the PI 3 -Akt/PKB pathway. Downstream of Akt/PKB, PTEN overexpression induced the transactivation of tumor suppressor protein, p53, by downregulating the expression of its inhibitor, MDM 2 . Decreased activity of PTEN induced by siRNA transfection of IMA SMCs diminished the negative regulation of PI 3 -Akt/PKB signaling leading to greater proliferative response induced by IGF-1 stimulation. Rb-phosphorylation in the SV SMCs occurred much earlier than the IMA cells and was quantitatively greater. Overexpression of PTEN in SV SMCs followed by IGF-1 stimulation caused no change in the R-point, but Rb phosphorylation was delayed as well as quantitatively reduced as compared to non-transfected cells. Increased activation of the IGF-1R-PI 3 K-Akt/PKB axis appears to be responsible for the higher rate of proliferation observed in SMCs of SV origin. Therefore, modulation of the PI 3 K-Akt/ PKB pathway via PTEN might be a novel and effective strategy in combating saphenous vein graft failure following CABG surgery. (Supported by National Institutes of Health grants R01 HL073349 and R01 HL070885)
Inspite of the improvements in its medical and surgical management Ischemic Heart Disease (IHD) is still the leading cause of morbidity and mortality in the Western world. Over the past few years the better understanding of the biology of vasculogenesis, angiogenesis and arteriogenesis has significantly increased the use of growth factors in the treatment and/or prevention ischemic heart disease by inducing blood vessel formation and thereby restoring/enriching the blood flow. Therapeutic angiogenesis makes use of the administration of a drug or angiogenic growth factor protein or gene to promote the development of endogenous collateral vessels in ischemic myocardium. Although growth factor therapy, primarily with VEGF and FGF has demonstrated great success in animal models, clinical trials have shown limitations in this treatment modality. Gene transfer and protein therapy are the two main approaches that have been used to achieve therapeutic angiogenesis. Most recently, interest has grown in the potential of cell-based gene transfer to induce myocardial angiogenesis. It is a promising new strategy, but still under its nascent stages, that uses autologous bone marrow cells or cultured stem cells transfected with a transgene of interest to express it in vivo. Although cell therapy holds promise for myocardial angiogenesis, many apprehensions still exist with regard to the methods currently available to track the transplanted cells, the capacity of these transplanted cells to phenotypically and functionally differentiate into cells of interest and whether they induce neovascularisation through secretion of growth factors. The right time/stage for the therapy, optimal gene delivery of the ideal angiogenic agent, appropriate design for the clinical trial and assessment of the outcome are still relevant questions that have to be answered. Science is quickening its pace towards better ideas in every field it has stepped into, particularly in the field of medicine. A time may not be far when we might be able to effectively cure IHD. But, "prevention is always better than cure".
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